Spectral MD Holdings, Ltd., a predictive analytics company, develops AI algorithms and optical technology in wound care treatment. The company is headquartered in Dallas, Texas.
| Revenue (TTM) | $16.93M |
| Gross Profit (TTM) | $7.78M |
| EBITDA | $-9.58M |
| Operating Margin | -49.40% |
| Return on Equity | -2308.00% |
| Return on Assets | -31.50% |
| Revenue/Share (TTM) | $0.59 |
| Book Value | $-0.28 |
| Price-to-Book | 26.08 |
| Price-to-Sales (TTM) | 3.27 |
| EV/Revenue | 3.263 |
| EV/EBITDA | -3.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -40.50% |
| Shares Outstanding | $31.82M |
| Float | $27.62M |
| % Insiders | 12.97% |
| % Institutions | 15.21% |
Volatility is currently contracting
Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education
DALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the British Burn Association (BBA) Annual Conference, held on June 17th – 19th at the Nottingham Trent University, Nottingham, England. The Company's DeepView® System was on display and was the subject of multiple podium and poster presentations during the conference, highlighting its contributions to advancing burn care through advanced diagnostic analysis across the globe.
Company Will Showcase FDA-Cleared DeepView® System for Burn Indication Company Will Showcase FDA-Cleared DeepView® System for Burn Indication
DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration (“FDA”).
DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System. With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States.
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA
DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received the “Small Business Innovator Award” at the inaugural Texas Innovation Conference, held on April 22-23, 2026 at the campus of Texas Christian University. The conference highlighted organizations and thought leaders that are turning research into real-world results, bringing together a select group of high-impact innovators, including startups, researchers, and ecosystem leaders.
DALLAS, April 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 12, 2026 after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.
DALLAS, April 22, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today shared a recap from the 2026 Annual Meeting of the American Burn Association, held April 14-17, 2026 in Orlando, Florida.
DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its 2026 Annual Meeting of Stockholders (“Annual Meeting”) will take place at 9:30 a.m. Central Daylight Time on Friday, May 29, 2026.
